EVERSANA announced expanded capabilities for its AI-powered commercialization platform, adding medical affairs and commercial workflow automation features. The update includes capabilities for medical information support, MLR automation, and analytics, designed to move beyond isolated AI pilots into scalable operations. The company says the platform uses agentic AI orchestration, workflow automation, and enterprise data capabilities to streamline content creation and knowledge management across medical and commercial teams. New solution areas mentioned include medical information support, market research, field sales engagement and patient services. EVERSANA’s CEO Mark Thierer is quoted positioning the announcement as an inflection point for how life sciences organizations deploy AI commercially, while also emphasizing governance and compliance expectations. For biotech and pharma operators, the practical takeaway is that commercialization support vendors are packaging AI into repeatable workflows tied to regulated processes—where documentation, traceability, and review cycles are central constraints.